Response by FcγR polymorphisms (best overall response)
| . | FcγR IIa . | FcγR IIIa . | ||||
|---|---|---|---|---|---|---|
| HR (n = 7) . | HH (n, 5) . | RR (n = 5) . | FF (n = 10) . | VV (n = 3) . | FV (n = 4) . | |
| Responder, n (%) | 2 (29) | 3 (60) | 3 (60) | 5 (50) | 2 (67) | 1 (25) |
| Nonresponder, n (%) | 5 (71) | 2 (40) | 2 (40) | 5 (50) | 1 (33) | 3 (75) |
| . | FcγR IIa . | FcγR IIIa . | ||||
|---|---|---|---|---|---|---|
| HR (n = 7) . | HH (n, 5) . | RR (n = 5) . | FF (n = 10) . | VV (n = 3) . | FV (n = 4) . | |
| Responder, n (%) | 2 (29) | 3 (60) | 3 (60) | 5 (50) | 2 (67) | 1 (25) |
| Nonresponder, n (%) | 5 (71) | 2 (40) | 2 (40) | 5 (50) | 1 (33) | 3 (75) |
Response was defined as CR/CRu or PR; nonresponse was defined as progressive disease or SD. FcγR polymorphism data were available for 20 patients.